Organization Profile

You just read:

Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation of Phase 3 Study of Zoptarelin Doxorubicin in Advanced Endometrial Cancer

News provided by

Aeterna Zentaris Inc.

Apr 27, 2015, 16:15 ET